近期,美国感染病学会(Infectious Diseases Society of America,IDSA)更新了耐药革兰阴性细菌感染的治疗指引。即《IDSA 2023版抗微生物药物耐药革兰阴性细菌感染治疗指引(IDSA 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-...
MDR病原微生物感染将会明显加重cIAI严重程度,恶化患者预后。评估MDR病原微生物感染风险、明确可能的病原微生物类型和药敏特征是我们为cIAI患者进行经验性抗感染治疗时首先需要考虑的问题。IDSA指南重点对不同类型和严重程度cIAI患者MDR病原微生物感染风险、病原微生物类型和抗感染治疗方案进行了总结和推荐,但不同国家...
Empirical combination antibiotic coverage for multi- samples are obtained 72 h after the initiation of appropriate drug-resistant (MDR) gram-negative bacilli, such as Pseudo- therapy (B-II). monas aeruginosa, should be used when CRBSI is suspected in 34. For long-term and short-term CRBSI ...
drug-resistant (MDR) gram-negative bacilli, such as Pseudo- monas aeruginosa, should be used when CRBSI is suspected in neutropenic patients, severely ill patients with sepsis, or patients known to be colonized with such pathogens, until the culture and susceptibility data are available and de-es...
MDRbacteriaatICUadmission.Inpatientswithpneumonia,adherencetoguidelineswasassociatedwithincreasedratesofappropriate initialantibiotictreatmentandde-escalation.ATS/IDSAcriteriahadanexcellentnegativepredictivevalueandalowpositivepredictive valueconcerninginfectionorcolonizationwithMDRbacteriaatICUadmission. ...